-
Your selected country is
France
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
Reported applications include immunoprecipitation and in vitro inhibition (in combination with a mAb to mouse CD11a) of T-cell proliferative responses to anti-CD3e mAb 145-2C11 (Cat. no. 553057) and allogeneic cells. We recommend our immunohistochemistry formulation of purified HM β1-1 mAb (Cat. No. 550530) for immunohistochemical staining (IHC) of rat tissues. For IHC of mouse tissues, we recommend the use of Purified Rat anti-Mouse CD29 mAb 9EG7 formulated for immunohistochemistry application (Cat. No. 550531).
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
The HM β1-1 monoclonal antibody specifically binds to the 130-kDa integrin β1 chain (CD29). CD29 is expressed on the cell surface as a heterodimer with one of the distinct integrin-α chains. With α1 through α6 (CD49a through CD49f), it forms the VLA-1 through VLA-6 complexes, respectively, and with αv (CD51), it forms αvβ1 integrin. It also associates with the integrin α7 α8, and α9 chains in non-lymphoid tissues. As a result, CD29 has a broad tissue distribution, including lymphocytes, endothelia, smooth muscle, epithelia, and oocytes. This hamster mAb to a mouse leukocyte antigen has been observed to crossreact with similar populations of rat leukocytes. Source of the immunogen was purified mouse VLA-4 (α4β1, CD49d/CD29).
Development References (6)
-
Jacobsen K, Miyake K, Kincade PW, Osmond DG.. Highly restricted expression of a stromal cell determinant in mouse bone marrow in vivo. J Exp Med. 1992; 176(4):927-935. (Biology). View Reference
-
Mendrick DL, Kelly DM. Temporal expression of VLA-2 and modulation of its ligand specificity by rat glomerular epithelial cells in vitro. Lab Invest. 1993; 69(6):690-702. (Clone-specific: Blocking). View Reference
-
Noto K, Kato K, Okumura K, Yagita H. Identification and functional characterization of mouse CD29 with a mAb. Int Immunol. 1995; 7(5):835-842. (Immunogen: Inhibition). View Reference
-
Springer TA. Adhesion receptors of the immune system. Nature. 1990; 346(6283):425-434. (Biology). View Reference
-
Wadsworth SA, Chang AC, Hong MJ, Halvorson MJ, Otto S, Coligan JE. Expression of a novel integrin beta 1 chain epitope and anti-beta 1 antibody-mediated enhancement of fibronectin binding are dependent on the stage of T cell differentiation. J Immunol. 1995; 154(5):2125-2133. (Immunogen: Blocking). View Reference
-
Wu X, Miyake K, Medina KL, Kincade PW, Gimble JM. Recognition of murine integrin beta 1 by a rat anti-stromal cell monoclonal antibody. Hybridoma. 1994; 13(5):409-416. (Immunogen). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.